PDS Biotechnology Stock Rating Upgraded by StockNews.com

PDS Biotechnology (NASDAQ:PDSB) received an upgrade from StockNews.com, moving from a "sell" rating to a "hold" rating in a research note released on Friday.

Additionally, several other brokerage firms have shared their insights on PDSB recently. HC Wainwright reaffirmed a "buy" rating with a price target of $21.00 in a report dated Thursday, October 24th. Furthermore, Alliance Global Partners elevated the stock to a "strong-buy" rating in their analysis on Wednesday, August 21st. Overall, one analyst presented a hold rating, while four analysts issued buy ratings and one recommended a strong buy for the stock. As noted by MarketBeat.com, PDS Biotechnology has an average rating of "Buy" and an average target price of $14.25.

PDS Biotechnology Stock Performance

The trading performance of PDSB increased by 0.3% on Friday, with the shares reaching $3.20. A total of 250,080 shares were traded, which is below the average trading volume of 610,675 shares. The company maintains a debt-to-equity ratio of 0.45, with a current ratio and quick ratio both at 3.84. Over the past year, PDS Biotechnology's stock has seen a low of $2.53 and a high of $6.85, boasting a market capitalization of $117.82 million, a PE ratio of -2.62, and a beta of 1.90. The stock's 50-day moving average price stands at $3.24, while the 200-day moving average price is $3.27.

PDS Biotechnology last published its earnings results on August 13th. For that quarter, the company reported an earnings per share (EPS) of ($0.23), exceeding the consensus estimate, which was ($0.31), by eight cents. In the same quarter the previous year, the company reported an EPS of ($0.37). Analysts predict that PDS Biotechnology will have an EPS of approximately -$1.24 for the current fiscal year.

Institutional Investor Activity

Recently, various institutional investors and hedge funds have changed their positions in PDSB. Vanguard Group Inc. increased its stake in PDS Biotechnology by 5.5% during the first quarter, bringing its total to 1,587,806 shares valued at around $6,288,000 after a purchase of 82,135 additional shares. Blair William & Co. IL raised its holdings in the company by 204.4% in the second quarter, now owning 121,743 shares worth $357,000 following the acquisition of 81,743 shares during the same period. Cubist Systematic Strategies LLC made a new investment in PDS Biotechnology during the second quarter, valued at approximately $146,000. Additionally, Squarepoint Ops LLC and Point72 Asia Singapore Pte. Ltd. also acquired new stakes in the stock during this period. Overall, institutional investors and hedge funds currently hold 26.84% of the company's stock.

PDS Biotechnology Overview

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm focused on developing targeted cancer immunotherapies in the United States. Their lead product candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials aimed at treating recurrent or metastatic head and neck cancer, as well as other human papillomavirus-associated malignancies.

PDSBiotechnology, Stock, Upgrade